Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody

PURPOSE: RG7116 is a novel anti-HER3 therapeutic antibody that inhibits HER3 signalling and induces antibody-dependent cellular cytotoxicity of tumor cells due to a glycoengineered antibody Fc moiety. We investigated the efficacy and pharmacokinetic/pharmacodynamic properties of HER3 signal inhibiti...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Chemother Pharmacol
Main Authors: Meneses-Lorente, Georgina, Friess, Thomas, Kolm, Irene, Hölzlwimmer, Gabriele, Bader, Sabine, Meille, Christophe, Thomas, Marlene, Bossenmaier, Birgit
Format: Artigo
Language:Inglês
Published: Springer Berlin Heidelberg 2015
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4365277/
https://ncbi.nlm.nih.gov/pubmed/25702049
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-015-2697-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items